221 related articles for article (PubMed ID: 15315862)
1. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.
Franssila R; Hedman K
Vaccine; 2004 Sep; 22(27-28):3809-15. PubMed ID: 15315862
[TBL] [Abstract][Full Text] [Related]
2. T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus b19.
Franssila R; Hokynar K; Hedman K
J Infect Dis; 2001 Mar; 183(5):805-9. PubMed ID: 11181158
[TBL] [Abstract][Full Text] [Related]
3. CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection.
Lindner J; Barabas S; Saar K; Altmann D; Pfister A; Fleck M; Deml L; Modrow S
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):356-61. PubMed ID: 16316401
[TBL] [Abstract][Full Text] [Related]
4. T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.
Franssila R; Auramo J; Modrow S; Möbs M; Oker-Blom C; Käpylä P; Söderlund-Venermo M; Hedman K
Clin Exp Immunol; 2005 Oct; 142(1):53-61. PubMed ID: 16178856
[TBL] [Abstract][Full Text] [Related]
5. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
[TBL] [Abstract][Full Text] [Related]
6. B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1.
Corcoran A; Mahon BP; Doyle S
J Infect Dis; 2004 May; 189(10):1873-80. PubMed ID: 15122524
[TBL] [Abstract][Full Text] [Related]
7. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface.
Rosenfeld SJ; Yoshimoto K; Kajigaya S; Anderson S; Young NS; Field A; Warrener P; Bansal G; Collett MS
J Clin Invest; 1992 Jun; 89(6):2023-9. PubMed ID: 1376332
[TBL] [Abstract][Full Text] [Related]
8. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples.
Beersma MF; Claas EC; Sopaheluakan T; Kroes AC
J Clin Virol; 2005 Sep; 34(1):71-5. PubMed ID: 15985386
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Th-cell immunity against human bocavirus and parvovirus B19: proliferation and cytokine responses are similar in magnitude but more closely interrelated with human bocavirus.
Kumar A; Filippone C; Lahtinen A; Hedman L; Söderlund-Venermo M; Hedman K; Franssila R
Scand J Immunol; 2011 Feb; 73(2):135-40. PubMed ID: 21198754
[TBL] [Abstract][Full Text] [Related]
10. IgE, CD8(+)CD60+ T cells and IFN-alpha in human immunity to parvovirus B19 in selective IgA deficiency.
Bluth MH; Norowitz KB; Chice S; Shah VN; Nowakowski M; Durkin HG; Smith-Norowitz TA
Hum Immunol; 2005 Oct; 66(10):1029-38. PubMed ID: 16386644
[TBL] [Abstract][Full Text] [Related]
11. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.
Von Landenberg P; Lehmann HW; Knöll A; Dorsch S; Modrow S
Arthritis Rheum; 2003 Jul; 48(7):1939-47. PubMed ID: 12847688
[TBL] [Abstract][Full Text] [Related]
12. Generation of a parvovirus B19 vaccine candidate.
Chandramouli S; Medina-Selby A; Coit D; Schaefer M; Spencer T; Brito LA; Zhang P; Otten G; Mandl CW; Mason PW; Dormitzer PR; Settembre EC
Vaccine; 2013 Aug; 31(37):3872-8. PubMed ID: 23827313
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay.
Bostic JR; Brown KE; Young NS; Koenig S
J Infect Dis; 1999 Mar; 179(3):619-26. PubMed ID: 9952368
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo cytokine responses against parvovirus B19 antigens in previously infected pregnant women.
Corcoran A; Mahon BP; McParland P; Davoren A; Doyle S
J Med Virol; 2003 Jul; 70(3):475-80. PubMed ID: 12767014
[TBL] [Abstract][Full Text] [Related]
15. Candidate recombinant vaccine for human B19 parvovirus.
Bansal GP; Hatfield JA; Dunn FE; Kramer AA; Brady F; Riggin CH; Collett MS; Yoshimoto K; Kajigaya S; Young NS
J Infect Dis; 1993 May; 167(5):1034-44. PubMed ID: 8486937
[TBL] [Abstract][Full Text] [Related]
16. Parvovirus B19 VP2-proteins produced in Saccharomyces cerevisiae: comparison with VP2-particles produced by baculovirus-derived vectors.
Lowin T; Raab U; Schroeder J; Franssila R; Modrow S
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):348-52. PubMed ID: 16316399
[TBL] [Abstract][Full Text] [Related]
17. Detection of parvovirus B19 NS1-specific antibodies by ELISA and western blotting employing recombinant NS1 protein as antigen.
Heegaard ED; Rasksen CJ; Christensen J
J Med Virol; 2002 Jul; 67(3):375-83. PubMed ID: 12116031
[TBL] [Abstract][Full Text] [Related]
18. IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay.
Manaresi E; Gallinella G; Zerbini M; Venturoli S; Gentilomi G; Musiani M
J Med Virol; 1999 Feb; 57(2):174-8. PubMed ID: 9892404
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.
Ballou WR; Reed JL; Noble W; Young NS; Koenig S
J Infect Dis; 2003 Feb; 187(4):675-8. PubMed ID: 12599085
[TBL] [Abstract][Full Text] [Related]
20. Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans.
Norbeck O; Isa A; Pöhlmann C; Broliden K; Kasprowicz V; Bowness P; Klenerman P; Tolfvenstam T
J Virol; 2005 Sep; 79(18):12117-21. PubMed ID: 16140790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
